The Latest Cardiac and Vascular News
– 2021 Fourth-Quarter Sales of $24.8 Billion reflecting growth of 10.4%, operational sales growth of 11.6%*, and adjusted operational sales growth of 12.3%* – 2021 Full-Year Sales of $93.8 Billion reflecting growth of 13.6%, operational sales growth of 12.2%*, and […]
– Sales of $18.3 billion reflecting a decline of 10.8%, operational decline of 9.0%* and adjusted operational decline of 8.8%*, primarily driven by the negative impact of the COVID-19 pandemic – EPS of $1.36 decreased 34.6%; adjusted EPS of $1.67 […]
– Sales of $20.7 billion reflecting strong growth of 3.3%, operational growth of 4.8%* and adjusted operational growth of 5.6%*, inclusive of the overall estimated negative impact of the COVID-19 pandemic – EPS of $2.17 increased 56.1%; adjusted EPS of […]
Johnson & Johnson, in collaboration with Apple, is offering eligible U.S. adults 65 years and older the opportunity to join the clinical study by downloading the Heartline Study app on iPhone Study aims to assess whether the Heartline Study app […]
NEW BRUNSWICK, N.J., April 16, 2019 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2019. “Our strong first-quarter results reflect continued underlying operational sales and adjusted EPS growth,” said Alex Gorsky, Chairman and Chief Executive Officer. “At the same time, we […]
IRVINE, Calif., Feb. 4, 2019 /PRNewswire/ — Johnson & Johnson Medical Devices Companies* announced today that Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of heart arrhythmias, has enrolled and treated the first patient in its U.S. Investigational Device […]
NEW BRUNSWICK, N.J., Jan. 22, 2019 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) today announced sales of $20.4 billion for the fourth quarter of 2018, an increase of 1.0% as compared to the fourth quarter of 2017. Operational sales results increased 3.3% and the negative […]
New Brunswick, NJ, January 17, 2019 — Johnson & Johnson (NYSE: JNJ) today announced that Janssen Pharmaceuticals, Inc., member of the Johnson & Johnson Family of Companies, entered into a research study in collaboration with Apple Inc. to investigate whether […]
IRVINE, Calif., SEPTEMBER 26 – Johnson & Johnson Medical Devices Companies* announced today that Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of heart arrhythmias, has received approval from the U.S. Food and Drug Administration (FDA) for […]
NICE, France, September 7, 2017 /PRNewswire/ — Johnson & Johnson Medical Devices Companies* today introduced CERENOVUS,** its new neurovascular business, at the European Society of Minimally Invasive Neurological Therapy (ESMINT) 9th Annual Meeting. CERENOVUS, a name derived from the Latin words for ‘new’ […]
